<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Amplia Therapeutics Ltd — News on 6ix</title>
<link>https://6ix.com/company/amplia-therapeutics-ltd</link>
<description>Latest news and press releases for Amplia Therapeutics Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 12:45:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/amplia-therapeutics-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683661da78dffbe2df15c23d.webp</url>
<title>Amplia Therapeutics Ltd</title>
<link>https://6ix.com/company/amplia-therapeutics-ltd</link>
</image>
<item>
<title>Accent Trial Mature Data Presented at International Conference</title>
<link>https://6ix.com/company/amplia-therapeutics-ltd/news/accent-trial-mature-data-presented-at-international-conference</link>
<guid isPermaLink="true">https://6ix.com/company/amplia-therapeutics-ltd/news/accent-trial-mature-data-presented-at-international-conference</guid>
<pubDate>Wed, 22 Apr 2026 12:45:00 GMT</pubDate>
<description>HIGHLIGHTS Mature data from Amplia’s ACCENT trial in pancreatic cancer is being presented at the prestigious American Association of Cancer Research (AACR) annual meetingThe ACCENT trial investigates the combination of narmafotinib with standard-of-care chemotherapyThe data presented includes additional analysis of the promising efficacy and survival data reported last month Melbourne, Australia, April 22, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics limited (ASX:ATX | OTCQB:INNMF), (“Amplia” or</description>
</item>
<item>
<title>Amplia Therapeutics Halts Recruitment in AMPLICITY Trial</title>
<link>https://6ix.com/company/amplia-therapeutics-ltd/news/amplia-therapeutics-halts-recruitment-in-amplicity-trial</link>
<guid isPermaLink="true">https://6ix.com/company/amplia-therapeutics-ltd/news/amplia-therapeutics-halts-recruitment-in-amplicity-trial</guid>
<pubDate>Tue, 07 Apr 2026 03:01:04 GMT</pubDate>
<description>Amplia Therapeutics Halts Recruitment in AMPLICITY Trial</description>
</item>
<item>
<title>Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial</title>
<link>https://6ix.com/company/amplia-therapeutics-ltd/news/amplia-therapeutics-reports-four-additional-complete-responses-and-improved-overall-survival-data-in-accent-pancreatic-cancer-trial</link>
<guid isPermaLink="true">https://6ix.com/company/amplia-therapeutics-ltd/news/amplia-therapeutics-reports-four-additional-complete-responses-and-improved-overall-survival-data-in-accent-pancreatic-cancer-trial</guid>
<pubDate>Mon, 23 Mar 2026 12:45:00 GMT</pubDate>
<description>HIGHLIGHTS Formal centralized and independent analysis of the clinical response data from the ACCENT trial has been undertaken and updated analysis provided to the CompanyThe data confirm that five (5) patients have achieved a complete response (CR) in the Phase 1b/2a trial of narmafotinib combined with chemotherapy resulting in an unprecedented rate of CRs of 7.8% (5/64)A median Overall Survival of 11.1 months has also been determined which is a 2 month improvement compared to chemotherapy alon</description>
</item>
<item>
<title>Amplia Reports Improved Responses & Survival in ACCENT trial</title>
<link>https://6ix.com/company/amplia-therapeutics-ltd/news/amplia-reports-improved-responses-and-survival-in-accent-trial</link>
<guid isPermaLink="true">https://6ix.com/company/amplia-therapeutics-ltd/news/amplia-reports-improved-responses-and-survival-in-accent-trial</guid>
<pubDate>Mon, 23 Mar 2026 02:56:06 GMT</pubDate>
<description>Amplia Reports Improved Responses & Survival in ACCENT trial</description>
</item>
<item>
<title>Trading Halt</title>
<link>https://6ix.com/company/amplia-therapeutics-ltd/news/trading-halt-550</link>
<guid isPermaLink="true">https://6ix.com/company/amplia-therapeutics-ltd/news/trading-halt-550</guid>
<pubDate>Thu, 19 Mar 2026 04:18:03 GMT</pubDate>
<description>Trading Halt</description>
</item>
<item>
<title>Pause in Trading</title>
<link>https://6ix.com/company/amplia-therapeutics-ltd/news/pause-in-trading-332</link>
<guid isPermaLink="true">https://6ix.com/company/amplia-therapeutics-ltd/news/pause-in-trading-332</guid>
<pubDate>Thu, 19 Mar 2026 03:13:04 GMT</pubDate>
<description>Pause in Trading</description>
</item>
<item>
<title>Amplia Therapeutics to Present at the Life Sciences Investor Forum on March 12th</title>
<link>https://6ix.com/company/amplia-therapeutics-ltd/news/amplia-therapeutics-to-present-at-the-life-sciences-investor-forum-on-march-12th</link>
<guid isPermaLink="true">https://6ix.com/company/amplia-therapeutics-ltd/news/amplia-therapeutics-to-present-at-the-life-sciences-investor-forum-on-march-12th</guid>
<pubDate>Wed, 11 Mar 2026 12:16:00 GMT</pubDate>
<description>The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorConferences.comMELBOURNE, Australia, March 11, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), focused on the development of drugs for pancreatic cancer, today announced that CEO and Managing Director Dr. Chris Burns, will present live at the</description>
</item>
<item>
<title>Poster Presentation Demonstrating Combination Benefit of Narmafotinib in Preclinical Kras-Mutated Cancer Models</title>
<link>https://6ix.com/company/amplia-therapeutics-ltd/news/poster-presentation-demonstrating-combination-benefit-of-narmafotinib-in-preclinical-kras-mutated-cancer-models</link>
<guid isPermaLink="true">https://6ix.com/company/amplia-therapeutics-ltd/news/poster-presentation-demonstrating-combination-benefit-of-narmafotinib-in-preclinical-kras-mutated-cancer-models</guid>
<pubDate>Mon, 09 Mar 2026 12:45:00 GMT</pubDate>
<description>HIGHLIGHTS Amplia’s lead drug narmafotinib enhances the activity of kRAS inhibitors in multiple preclinical cancer models presented at US conferenceData showing narmafotinib activity in preclinical models of pancreatic cancer, lung cancer and ovarian cancer are presentedThe development of kRAS inhibitors for different types of solid tumors is currently an area of intense global activity Melbourne, Australia, March 09, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (</description>
</item>
<item>
<title>Amplia Therapeutics Announces Opening of US Sites for Amplicity Pancreatic Cancer Trial</title>
<link>https://6ix.com/company/amplia-therapeutics-ltd/news/amplia-therapeutics-announces-opening-us-134500542</link>
<guid isPermaLink="true">https://6ix.com/company/amplia-therapeutics-ltd/news/amplia-therapeutics-announces-opening-us-134500542</guid>
<pubDate>Wed, 11 Feb 2026 13:45:00 GMT</pubDate>
<description>Melbourne, Australia, Feb. 11, 2026 (GLOBE NEWSWIRE) -- HIGHLIGHTS Two US-based sites have completed trial initiation activities for the AMPLICITY trial in pancreatic cancer These sites join the two Australian sites already open and recruiting patients Three additional US sites are expected to be open in the coming weeks Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), announces that two (2) sites in the US have been initiated and will shortly be commencing recrui</description>
</item>
<item>
<title>Amplia Therapeutics - Quarterly Activities and Cash Flow Reports - December 2025</title>
<link>https://6ix.com/company/amplia-therapeutics-ltd/news/amplia-therapeutics-quarterly-activities-cash-134500642</link>
<guid isPermaLink="true">https://6ix.com/company/amplia-therapeutics-ltd/news/amplia-therapeutics-quarterly-activities-cash-134500642</guid>
<pubDate>Fri, 30 Jan 2026 13:45:00 GMT</pubDate>
<description>Melbourne, Australia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Key Highlights from the Quarter ACCENT Trial Success: The ACCENT trial, testing narmafotinib with gemcitabine and Abraxane®, continues to demonstrate that narmafotinib is well tolerated by patients whilst enhancing the effects of chemotherapyAMPLICITY Trial Initiation: The Phase 1b/2a AMPLICITY trial has started, combining narmafotinib with FOLFIRINOX chemotherapy, aiming to determine the optimal daily dose. Patient recruitment is ongoing i</description>
</item>
<item>
<title>Quarterly Activities/Appendix 4C Cash Flow Report</title>
<link>https://6ix.com/company/amplia-therapeutics-ltd/news/quarterly-activitiesappendix-4c-cash-flow-report-63</link>
<guid isPermaLink="true">https://6ix.com/company/amplia-therapeutics-ltd/news/quarterly-activitiesappendix-4c-cash-flow-report-63</guid>
<pubDate>Fri, 30 Jan 2026 02:49:22 GMT</pubDate>
<description>Quarterly Activities/Appendix 4C Cash Flow Report</description>
</item>
<item>
<title>NARMAFOTINIB Large-Scale Manufactre Complete</title>
<link>https://6ix.com/company/amplia-therapeutics-ltd/news/narmafotinib-large-scale-manufactre-complete-133000799</link>
<guid isPermaLink="true">https://6ix.com/company/amplia-therapeutics-ltd/news/narmafotinib-large-scale-manufactre-complete-133000799</guid>
<pubDate>Thu, 22 Jan 2026 13:30:00 GMT</pubDate>
<description>Successful completion of the first large-scale manufacture of narmafotinib which produced approx. 13 kg of drug Successful transition of process and production from an R&D facility to a commercial manufacturing environment - a key step in Phase-3 readiness Sufficient drug supply to support Amplia’s pancreatic cancer trials and other planned studies, supporting the Company's clinical development pipeline Melbourne, Australia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX;</description>
</item>
<item>
<title>ACCENT DATA PRESENTED AT 2026 ASCO GASTROINTESTINAL CANCER SYMPOSIUM</title>
<link>https://6ix.com/company/amplia-therapeutics-ltd/news/accent-data-presented-2026-asco-134500348</link>
<guid isPermaLink="true">https://6ix.com/company/amplia-therapeutics-ltd/news/accent-data-presented-2026-asco-134500348</guid>
<pubDate>Mon, 12 Jan 2026 13:45:00 GMT</pubDate>
<description>HIGHLIGHTS Results from the Phase 2a ACCENT trial in pancreatic cancer have been presented at the specialist conference ASCO Gastrointestinal Cancer SymposiumUpdated data analysis continues to show that Narmafotinib combination compares favourably with gemcitabine and Abraxane combination alone Melbourne, Australia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), is pleased to announce that interim data from the ongoing ACCENT tr</description>
</item>
<item>
<title>Amplia Therapeutics to Present at 2026 ASCO Gastrointestinal Cancers Symposium</title>
<link>https://6ix.com/company/amplia-therapeutics-ltd/news/amplia-therapeutics-present-2026-asco-134500217</link>
<guid isPermaLink="true">https://6ix.com/company/amplia-therapeutics-ltd/news/amplia-therapeutics-present-2026-asco-134500217</guid>
<pubDate>Tue, 23 Dec 2025 13:45:00 GMT</pubDate>
<description>Melbourne, Australia, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF) (“Amplia” or the “Company”) is pleased to announce that the Company’s CMO Dr Jason Lickliter will present a poster at the forthcoming ASCO Gastrointestinal Cancers Symposium, being held January 8-10, 2026, in San Francisco. The poster, titled Narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel as first-line treatment for patients with metastatic pancreatic cancer (ACCEN</description>
</item>
<item>
<title>Amplia Enters into Second Agreement with Korean Specialist Drug Screening Company Next&Bio to Explore Combination Therapy with FAK Inhibitor and kRAS Inhibitors</title>
<link>https://6ix.com/company/amplia-therapeutics-ltd/news/amplia-enters-second-agreement-korean-134500933</link>
<guid isPermaLink="true">https://6ix.com/company/amplia-therapeutics-ltd/news/amplia-enters-second-agreement-korean-134500933</guid>
<pubDate>Fri, 19 Dec 2025 13:45:00 GMT</pubDate>
<description>HIGHLIGHTS The preclinical research collaboration with specialist drug screening company Next & Bio has been extendedThe collaboration explores the effect of Amplia’s FAK inhibitors in combination with experimental drugs called kRas inhibitorskRas inhibitors are being developed for the treatment of pancreatic cancer and other solid tumours Melbourne, Australia, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), is pleased to announc</description>
</item>
<item>
<title>Additional Confirmed Response Reported as Part of Amplia Investor Presentation</title>
<link>https://6ix.com/company/amplia-therapeutics-ltd/news/additional-confirmed-response-reported-part-134500948</link>
<guid isPermaLink="true">https://6ix.com/company/amplia-therapeutics-ltd/news/additional-confirmed-response-reported-part-134500948</guid>
<pubDate>Fri, 12 Dec 2025 13:45:00 GMT</pubDate>
<description>HIGHLIGHTS An additional confirmed partial response has been recorded in the ongoing ACCENT trialThis brings the confirmed Objective Response Rate to 35%Updated data to be presented at the Life Sciences Virtual Investor Forum Melbourne, Australia, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), is pleased to announce that an additional confirmed partial response (PR) has been recorded in the ongoing ACCENT trial in metastatic pan</description>
</item>
<item>
<title>Amplia Therapeutics Limited to Present at the Life Sciences Virtual Investor Forum December 11th</title>
<link>https://6ix.com/company/amplia-therapeutics-ltd/news/amplia-therapeutics-limited-present-life-172400255</link>
<guid isPermaLink="true">https://6ix.com/company/amplia-therapeutics-ltd/news/amplia-therapeutics-limited-present-life-172400255</guid>
<pubDate>Mon, 08 Dec 2025 17:24:00 GMT</pubDate>
<description>Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.comMELBOURNE, Vic, Australia, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (OTCQB:INNMF ASX:ATX), based in Melbourne, Australia and focused on developing new therapies for hard to treat cancers, today announced that Dr Chris Burns, CEO and Managing Director, will present live at Life Sciences Virtual Investor Forum hosted by VirtualInvestorConf</description>
</item>
<item>
<title>Key Narmafotinib Patent Granted in the U.S.</title>
<link>https://6ix.com/company/amplia-therapeutics-ltd/news/key-narmafotinib-patent-granted-u-134500453</link>
<guid isPermaLink="true">https://6ix.com/company/amplia-therapeutics-ltd/news/key-narmafotinib-patent-granted-u-134500453</guid>
<pubDate>Wed, 03 Dec 2025 13:45:00 GMT</pubDate>
<description>Highlights The Company has received a Certificate of Grant from the US Patent and Trademark Office for a key patent for the FAK inhibitor narmafotinibThe patent extends protection for narmafotinib to at least 2040 Melbourne, Australia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), announces that it has received formal notification from the US Patent and Trademark Office (USPTO) that a key patent titled A salt and crystal form o</description>
</item>
<item>
<title>Half Yearly Report and Accounts</title>
<link>https://6ix.com/company/amplia-therapeutics-ltd/news/half-yearly-report-and-accounts-249</link>
<guid isPermaLink="true">https://6ix.com/company/amplia-therapeutics-ltd/news/half-yearly-report-and-accounts-249</guid>
<pubDate>Thu, 27 Nov 2025 11:04:14 GMT</pubDate>
<description>Half Yearly Report and Accounts</description>
</item>
<item>
<title>Positive Response from US FDA to Amplia's Type D Meeting</title>
<link>https://6ix.com/company/amplia-therapeutics-ltd/news/positive-response-from-us-fda-to-amplias-type-d-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/amplia-therapeutics-ltd/news/positive-response-from-us-fda-to-amplias-type-d-meeting</guid>
<pubDate>Thu, 20 Nov 2025 04:20:08 GMT</pubDate>
<description>Positive Response from US FDA to Amplia's Type D Meeting</description>
</item>
</channel>
</rss>